172 related articles for article (PubMed ID: 23933815)
1. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.
Passante E; Würstle ML; Hellwig CT; Leverkus M; Rehm M
Cell Death Differ; 2013 Nov; 20(11):1521-31. PubMed ID: 23933815
[TBL] [Abstract][Full Text] [Related]
2. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Lillehammer T; Engesaeter BO; Prasmickaite L; Maelandsmo GM; Fodstad O; Engebraaten O
J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
[TBL] [Abstract][Full Text] [Related]
5. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
Engesæter B; Engebraaten O; Flørenes VA; Mælandsmo GM
PLoS One; 2012; 7(9):e45492. PubMed ID: 23029050
[TBL] [Abstract][Full Text] [Related]
6. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Weyhenmeyer BC; Noonan J; Würstle ML; Lincoln FA; Johnston G; Rehm M; Murphy BM
Oncotarget; 2016 Sep; 7(38):61295-61311. PubMed ID: 27494880
[TBL] [Abstract][Full Text] [Related]
7. Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism.
Vetma V; Guttà C; Peters N; Praetorius C; Hutt M; Seifert O; Meier F; Kontermann R; Kulms D; Rehm M
Cell Death Differ; 2020 Aug; 27(8):2417-2432. PubMed ID: 32081986
[TBL] [Abstract][Full Text] [Related]
8. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins.
Shibuya H; Kato Y; Saito M; Isobe T; Tsuboi R; Koga M; Toyota H; Mizuguchi J
Melanoma Res; 2003 Oct; 13(5):457-64. PubMed ID: 14512787
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC
Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763
[TBL] [Abstract][Full Text] [Related]
11. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
12. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
Ding B; Wu X; Fan W; Wu Z; Gao J; Zhang W; Ma L; Xiang W; Zhu Q; Liu J; Ding X; Gao S
Int J Nanomedicine; 2011; 6():1991-2005. PubMed ID: 21976975
[TBL] [Abstract][Full Text] [Related]
13. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
14. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment.
Olszewska-Słonina DM; Styczyńisk J; Drewa TA; Olszewski KJ; Czajkowski R
Acta Pol Pharm; 2005; 62(6):473-83. PubMed ID: 16583988
[TBL] [Abstract][Full Text] [Related]
15. The curcumin analog DM-1 induces apoptotic cell death in melanoma.
Faião-Flores F; Suarez JA; Maria-Engler SS; Soto-Cerrato V; Pérez-Tomás R; Maria DA
Tumour Biol; 2013 Apr; 34(2):1119-29. PubMed ID: 23359272
[TBL] [Abstract][Full Text] [Related]
16. Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma.
Rožanc J; Sakellaropoulos T; Antoranz A; Guttà C; Podder B; Vetma V; Rufo N; Agostinis P; Pliaka V; Sauter T; Kulms D; Rehm M; Alexopoulos LG
Cell Death Differ; 2019 Aug; 26(8):1365-1378. PubMed ID: 30323272
[TBL] [Abstract][Full Text] [Related]
17. Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
Risberg K; Fodstad O; Andersson Y
J Immunother; 2010 Apr; 33(3):272-8. PubMed ID: 20445347
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
Sarif Z; Tolksdorf B; Fechner H; Eberle J
Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
[TBL] [Abstract][Full Text] [Related]
19. Parthenolide enhances dacarbazine activity against melanoma cells.
Koprowska K; Hartman ML; Sztiller-Sikorska M; Czyz ME
Anticancer Drugs; 2013 Sep; 24(8):835-45. PubMed ID: 23797801
[TBL] [Abstract][Full Text] [Related]
20. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kurbanov BM; Geilen CC; Fecker LF; Orfanos CE; Eberle J
J Invest Dermatol; 2005 Nov; 125(5):1010-9. PubMed ID: 16297203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
